Mtor Inhibitors For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
mTOR (mechanistic target of rapamycin) inhibitors have emerged as a promising therapeutic approach for neurodegenerative diseases. The mTOR pathway is a central regulator of cell growth, metabolism, and autophagy. In neurodegenerative conditions, hyperactivation of mTORC1 leads to impaired autophagy and accumulation of toxic protein aggregates. mTOR inhibition can restore autophagic flux and promote clearance of misfolded proteins in Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). [1]
mTOR inhibitors work through several key mechanisms: [2]
| Mechanism | Description | [3]
|-----------|-------------| [4]
| Autophagy Induction | Inhibit mTORC1 to activate ULK1 complex and initiate autophagy | [5]
| Protein Aggregate Clearance | Enhance clearance of Aβ, tau, α-synuclein, and mutant huntingtin | [6]
| Synaptic Plasticity | Improve LTP and memory in animal models of AD | [7]
| Neuroinflammation | Reduce microglial activation and inflammatory cytokine production |
| Mitochondrial Function | Improve mitochondrial biogenesis and function |
| Type | Examples | Mechanism | Advantages |
|---|---|---|---|
| Allosteric (Rapalogs) | Rapamycin, Everolimus | FKBP12-dependent | Better tolerability |
| ATP-Competitive | Torin 1, AZD8055 | Direct mTOR kinase inhibition | More potent; inhibit both mTORC1/2 |
| Trial | Drug | Phase | Status | Indication |
|---|---|---|---|---|
| NCT02955589 | Everolimus | II | Completed | Alzheimer's disease (RADAR) |
| NCT03763955 | Sirolimus | II | Recruiting | Parkinson's disease |
| NCT04297683 | Everolimus | II | Completed | ALS |
| NCT04629495 | Rapamycin | II | Recruiting | Huntington's disease |
mTOR inhibitors show synergy with:
Current research focuses on:
The study of Mtor Inhibitors For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Caccamo A, et al. mTOR regulates memory and synaptic plasticity. 2020. ↩︎
Bhaskaran S, et al. Rapamycin and mTOR inhibitors in Alzheimer's disease. 2020. ↩︎
Liu K, et al. Autophagy enhancement by rapamycin ameliorates α-synuclein toxicity. 2019. ↩︎
Ravikumar B, et al. Rapamycin and mTOR inhibition in Huntington's disease. 2020. ↩︎
Martinez A, et al. and clinical evidence. ↩︎
Bendotti C, et al. Rapamycin attenuates disease in SOD1 mice. 2021. ↩︎
Ozcelik S, et al. mTOR in neurodegenerative diseases. 2022. ↩︎